Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” Ozempic found outside the authorized drug supply chain. The contents of the ...

Nvidia introduced the Blackwell Ultra and Vera Rubin, its most powerful AI chips to date, amid escalating demand for AI ...

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Elon Musk plans to devote more time to Tesla. Musk's political agenda has hurt Tesla's reputation, resulting in slowing vehicle sales. Net income slid 71% in the first quarter, and adjusted earnings ...

The electric-vehicle maker will report results after markets close. Analysts expect a year-over-year drop in profit, FactSet estimates show. Tesla stock, which has fallen 44% this year through Monday, ...

Novo Nordisk A/S (NYSE:NVO) shares fell as much as 8% in Thursday trading after news emerged about a competitor’s successful drug trial.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

Ozempic, a medication to help manage diabetes, has shot up in popularity in the US. So much so, that the US Food and Drug Administration (FDA) has issued a warning against using counterfeit Ozempic, ...